Combined Immune Checkpoint Blockade

被引:12
|
作者
Drake, Charles G. [1 ,2 ,3 ,4 ]
机构
[1] James Buchanan Brady Urol Inst, Dept Oncol, Baltimore, MD USA
[2] James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
关键词
ACTIVATED T-CELLS; CANCER-IMMUNOTHERAPY; EFFECTOR FUNCTION; OVARIAN-CANCER; REGULATORY T; LAG-3; PD-1; IPILIMUMAB; AUTOIMMUNE; TIM-3;
D O I
10.1053/j.seminoncol.2015.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the majority of cancer patients. Immune checkpoint blockade can be combined with several other interventions, including radiation therapy, chemotherapy and cancer vaccines. However, the observation that T cells that are rendered not-responsive or "exhausted" by recognition of tumor antigens express multiple non-overlapping checkpoint molecules suggests that immunotherapy approaches in which multiple checkpoint molecules are blocked may be particularly active in the clinic. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:656 / 662
页数:7
相关论文
共 50 条
  • [31] Delivery Strategies for Immune Checkpoint Blockade
    Chen, Qian
    Wang, Chao
    Chen, Guojun
    Hu, Quanyin
    Gu, Zhen
    [J]. ADVANCED HEALTHCARE MATERIALS, 2018, 7 (20)
  • [32] Eosinophilic Fasciitis with Immune Checkpoint Blockade
    Becker, Sophie
    Garzarolli, Marlene
    Meisterfeld, Susann
    Beissert, Stefan
    Meier, Friedegund
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 32 - 32
  • [33] Immune checkpoint blockade: timing is everything
    Sinicrope, Frank A.
    Turk, Mary Jo
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 3
  • [34] Hallmarks of response to immune checkpoint blockade
    Alexandria P Cogdill
    Miles C Andrews
    Jennifer A Wargo
    [J]. British Journal of Cancer, 2017, 117 : 1 - 7
  • [35] The future of microfluidics in immune checkpoint blockade
    Briones, Jonathan
    Espulgar, Wilfred
    Koyama, Shohei
    Takamatsu, Hyota
    Tamiya, Eiichi
    Saito, Masato
    [J]. CANCER GENE THERAPY, 2021, 28 (09) : 895 - 910
  • [36] Activation of phagocytosis by immune checkpoint blockade
    Li, Chia-Wei
    Lai, Yun-Ju
    Hsu, Jennifer L.
    Hung, Mien-Chie
    [J]. FRONTIERS OF MEDICINE, 2018, 12 (04) : 473 - 480
  • [37] Sarcoidosis, malignancy and immune checkpoint blockade
    Gaughan, Elizabeth M.
    [J]. IMMUNOTHERAPY, 2017, 9 (13) : 1051 - 1053
  • [38] Fighting ageing with immune checkpoint blockade
    Sarah Crunkhorn
    [J]. Nature Reviews Drug Discovery, 2023, 22 : 17 - 17
  • [39] Immune checkpoint blockade in infectious diseases
    Michelle N. Wykes
    Sharon R. Lewin
    [J]. Nature Reviews Immunology, 2018, 18 : 91 - 104
  • [40] Fighting ageing with immune checkpoint blockade
    Crunkhorn, Sarah
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (01) : 17 - 17